Award Year
2015
Award Type
Targeted: Novel Outcome Measures for ASD Clinical Trials
Awardees
Pamela Ventola
SFARI Investigator
Frederick Shic
SFARI Investigator
Bringing people and ideas together to fund, conduct, and share transformative science.
Our grants advance knowledge and strengthen connections between science and society.
Discover the latest news, research, and updates.
We convene scientists, mathematicians, and thinkers to share ideas and explore new questions.
Founded by Jim and Marilyn Simons, we’re a private philanthropy advancing mathematics and basic science.
Work with us on the frontier of basic science research.
The Flatiron Institute is a research center that uses computational science to advance fields like physics, biology, and astronomy.
Search
Funded Work
2015
Targeted: Novel Outcome Measures for ASD Clinical Trials
SFARI Investigator
SFARI Investigator
Eye-tracking is a well-established research tool that can be used to study social cognition in individuals with autism spectrum disorder (ASD). Previous work at the Yale Child Study Center has shown that eye-tracking techniques are robust measures of atypical social-information processing across the lifespan in individuals with ASD.
For the past 10 years, Frederick Shic, an Associate Professor at University of Washington/Seattle Children’s Research Institute, has been designing new and innovative ways to acquire and analyze the complex signals obtained from eye-tracking systems, together with Katarzyna Chawarska, an expert in autism and visual social cognition. Shic and his collaborators are now focusing on the development of eye-tracking tools and paradigms for practical use.
Pamela Ventola, clinical director of the Center for Translational Developmental Neuroscience at the Yale Child Study Center, directs a behavioral treatment program for individuals with ASD.
Shic and Ventola’s teams are collaborating on the current project, which aims to implement innovative eye-tracking paradigms measuring the direct effects of pivotal response treatment (PRT) in 4- to 7-year-old children with ASD over the course of a 16-week treatment period. They will also test the potential of augmenting the accessibility of eye-tracking technologies by providing participants with mobile tablets equipped with paradigms designed for home monitoring.
Shic and Ventola will be among the first researchers to use an advanced, multi-paradigm and multi-system approach to evaluate the use of eye-tracking for treatment monitoring by pairing it with an evidence-based behavioral intervention. This work is a crucial step toward providing more sensitive, robust and accessible treatment monitoring for individuals with ASD and for outcome measures in clinical trials.